Trials / Completed
CompletedNCT02867735
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
A Randomized, Single-masked, Sham-control, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema From Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (AMD), or Retinal Vein Occlusions (RVO)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
Conditions
- Macular Edema
- Diabetic Macular Edema
- Neovascular Age-related Macular Degeneration
- Retinal Vein Occlusions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LKA651 | Interventional |
| OTHER | Sham Comparator |
Timeline
- Start date
- 2016-09-21
- Primary completion
- 2018-02-15
- Completion
- 2018-02-15
- First posted
- 2016-08-16
- Last updated
- 2022-04-15
Locations
6 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02867735. Inclusion in this directory is not an endorsement.